Sugi Predict

Sugi Predict / Compounds / SCHEMBL3402296

SCHEMBL3402296

SCHEMBL3402296

CCOC(=O)c1nnn(-c2ccc(F)cc2)c1C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.75
▸ ALOX12 P18054 1/20 0.75
▸ MAPT P10636 2/20 0.69
▸ PTGS2 P35354 2/20 0.68
▸ SLC5A1 P13866 3/20 0.65
▸ SLC5A2 P31639 3/20 0.65
▸ CA1 P00915 1/20 0.61
▸ CA2 P00918 1/20 0.61
▸ CA4 P22748 1/20 0.61
▸ CA9 Q16790 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ KMT2A Q03164 3/20 0.55
▸ LMNA P02545 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ HPGD P15428 1/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ GABRA2 P47869 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28604810 0.86 SMN1; SMN2 (0.75) TP53ALOX12MAPTPTGS2SLC5A1
SCHEMBL3405863 0.86 TP53 (0.67) TP53ALOX12MAPTPTGS2SLC5A1
SCHEMBL3406088 0.86 PTGS2 (0.71) TP53ALOX12MAPTPTGS2CA1
SCHEMBL6280740 0.86 TP53 (1.00) TP53ALOX12MAPTSLC5A1SLC5A2
SCHEMBL3400622 0.85 TP53 (0.66) TP53ALOX12MAPTPTGS2SLC5A1
SCHEMBL15882211 0.85 SMN1; SMN2 (0.77) TP53ALOX12MAPTSLC5A1SLC5A2
SCHEMBL38652895 0.84 SLC5A1 (0.60) TP53ALOX12MAPTPTGS2SLC5A1
SCHEMBL3406737 0.84 TP53 (0.64) TP53ALOX12MAPTPTGS2SLC5A1
SCHEMBL3406655 0.82 POLB (0.62) TP53ALOX12MAPTPTGS2SLC5A1
SCHEMBL3406954 0.82 ALOX12 (0.69) TP53ALOX12MAPTSLC5A1SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180189-B2 Proteostasis regulators Kineta, Inc. (US) 2024-12-31 — — US disclosed
US-11691992-B2 Oxaborole analogs and uses thereof ANACOR PHARMACEUTICALS, INC. (US) 2023-07-04 — — US disclosed
US-11691992-B2 Oxaborole analogs and uses thereof ANACOR PHARMACEUTICALS, INC. (US) 2023-07-04 — — US disclosed
US-20210253605-A1 NOVEL OXABOROLE ANALOGS AND USES THEREOF ANACOR PHARMACEUTICALS INC (US) 2021-08-19 — — US disclosed
US-10961261-B2 Oxaborole analogs and uses thereof ANACOR PHARMACEUTICALS, INC. (US) 2021-03-30 — — US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 — — US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 — — US disclosed
EP-3552664-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2019-10-16 — — EP disclosed
EP-2707101-B1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS INC (US) 2019-02-13 — — EP disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 — — US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 — — US disclosed
EP-2707101-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2014-03-19 — — EP disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 — — US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 — — US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 — — US disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 — — WO disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 — — WO disclosed
EP-2252599-A1 TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY Glaxo Group Limited (GB) 2010-11-24 — — EP disclosed
WO-2009115486-A1 TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY GLAXO GROUP LIMITED (GB) 2009-09-24 — — WO disclosed
WO-2009115486-A1 TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY GLAXO GROUP LIMITED (GB) 2009-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299270-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 TP53 126/4885ALOX12 3731/4885MAPT 577/4885
US-11691992-B2 Oxaborole analogs and uses thereof OXA1L, EPX, OAT TP53 4500/4885ALOX12 275/4885MAPT 4347/4885
US-20210253605-A1 NOVEL OXABOROLE ANALOGS AND USES THEREOF OXA1L, AOX1, EPX TP53 4700/4885ALOX12 568/4885MAPT 4266/4885
US-20170247355-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 TP53 126/4885ALOX12 3731/4885MAPT 577/4885
US-12180189-B2 Proteostasis regulators PSMG3, VCP, HSPA5 TP53 126/4885ALOX12 3731/4885MAPT 577/4885
US-10961261-B2 Oxaborole analogs and uses thereof OXA1L, EPX, OAT TP53 4500/4885ALOX12 275/4885MAPT 4347/4885
US-20120316193-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 TP53 126/4885ALOX12 3731/4885MAPT 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.